Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

Core Viewpoint - Moderna's stock has been trending recently, with a return of -3.8% over the past month, outperforming the Zacks S&P 500 composite's -7.5% change, while the Zacks Medical - Biomedical and Genetics industry saw a loss of 0.6% [1] Earnings Estimates Revisions - For the current quarter, Moderna is expected to report a loss of $2.90 per share, reflecting a change of +5.5$10.03, indicating a change of -13.1% from the previous year, with a recent change of -4.3% [4] - For the next fiscal year, the consensus estimate of -$7.02 shows a change of +29.9$142.28 million, indicating a year-over-year change of -14.8% [8] - For the current fiscal year, the sales estimate is $2.2 billion, reflecting a change of -31.9$3.01 billion indicates a change of +36.7% [8] Last Reported Results and Surprise History - In the last reported quarter, Moderna's revenues were $966 million, representing a year-over-year decline of -65.6$2.50 compared to $0.55 a year ago [9] - The reported revenues exceeded the Zacks Consensus Estimate of$956.11 million by +1.04%, and the EPS surprise was +7.06% [10] - Moderna has consistently beaten consensus EPS and revenue estimates in the trailing four quarters [10] Valuation - Moderna is graded F in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [14] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for determining whether the stock is overvalued, fairly valued, or undervalued [12][13] Bottom Line - The current Zacks Rank of 3 suggests that Moderna may perform in line with the broader market in the near term, despite the market buzz surrounding the company [15]